Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Immunotherapy"
DOI: 10.2217/imt-2022-0058
Abstract: Most advanced colorectal cancer patients with proficient DNA mismatch repair or microsatellite stability (MSS) are insensitive to immune checkpoint inhibitor therapy. This report describes a heavily pretreated refractory colon adenocarcinoma patient with MSS. After experiencing… read more here.
Keywords: bevacizumab chemotherapy; long term; sintilimab bevacizumab; heavily pretreated ... See more keywords